Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03363100 · ClinicalTrials.gov registry record · NA
Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c
A NA study of Diabetes Mellitus, Type 2, sponsored by Evidation Health.
- Completed
- Registry status
- NA
- Development phase
- 624
- Enrollment target
- 1
- Study location
NCT03363100: Completed NA study of Diabetes Mellitus, Type 2, sponsored by Evidation Health.
NCT03363100 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by Evidation Health. The registered enrollment target is 624 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03363100, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by Evidation Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 624 participants
- Enrollment target
- 1
- Study location
Study Summary
The Diabetes Coaching Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Health Partnership on A1c levels for individuals with uncontrolled Type 2 diabetes.
Primary Outcome
Change in A1c from study baseline to study end for participants
Conditions Studied
Interventions
- BEHAVIORAL Digital health Partnership program
Study Locations (1)
California
- Evidation Health - San Mateo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2017-12-05 |
| Est. Completion | 2019-02-23 |
| Phase | NA |
What the finished NCT03363100 record still lists
NCT03363100 is an interventional study that assigns participants to a tested intervention. The registered 624 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Digital health Partnership program is the first listed.
NCT03363100 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03363100 about?
NCT03363100 is a clinical study titled "Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c". The Diabetes Coaching Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Health Partnership on A1c levels for individuals with uncontrolle...
What is the current status of trial NCT03363100?
This trial is currently completed. It is a NA study. The enrollment target is 624 participants. The study started on 2017-12-05. Estimated completion is 2019-02-23.
What conditions does trial NCT03363100 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT03363100?
The interventions under investigation include: Digital health Partnership program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03363100?
This trial is sponsored by Evidation Health, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03363100 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03363100's enrollment target sits among peer trials
624 62nd of 348 higher than 287 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI